

1642



RECEIVED
JUN 23 2003
TC 1700

PATENT

Attorney Docket No.: 8830-113 (formerly A-67653/DCA/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

29
SM
6/28/03

In re:	Patent application of	:	
	Robert James Mason, et al	:	
Serial No.:	09/230,955	:	Group Art Unit:
		:	1642
Filed:	May 04, 1999	:	Examiner:
		:	Karen A. Cannella
For:	Assessment of Cervical Cells	:	

RECEIVED

JUN 24 2003

Supplemental Response

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action dated May 20, 2003 in the above application. No fee is believed due by the filing of this response, however should any fees be deemed due, please charge Deposit Account number 50-0573

Kindly correct the following inadvertent error in the Amendment in Response to Office Action which was timely filed on January 29, 2003:

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BY: Sherry R. Smith

DATE: 6/16/03


In the "Marked-Up Version of the Claims" please substitute the marked-up version of claim 3 with the following:

3. (Amended three times) A method of determining a premalignant or neoplastic disease state in a cervical smear sample containing cells of the cervix, the method comprising contacting [one] a panel of two or more monoclonal antibodies with said sample, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein [said] the percentage binding of the two or more monoclonal antibodies [detect cellular markers which differ between normal and] to premalignant or neoplastic cells is decreased with respect to normal cells, and wherein the panel includes one or more monoclonal antibodies [comprise] comprising one or more polypeptides each comprising an antigen binding domain obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.

Applicants thank the Examiner for pointing out the inadvertent error in the prior Response and apologize for the oversight.

Respectfully submitted,

ROBERT JAMES MASON *et al.*

BY 

DANIEL A. MONACO
Registration No. 30,480
DRINKER, BIDDLE & REATH LLP.
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103
(215) 988-3312 ph.
(215) 988-2757 fax
Attorney for Applicants